Kawasaki Disease (KD) (also known as Kawasaki Syndrome) is a rare form of vasculitis which affects children and is characterised by inflammation of the medium sized blood vessels throughout the body.
The coronary arteries (arteries supplying the heart muscle) are the commonest arteries affected.
The main concern in children is that inflammation of the coronary arteries can lead to aneurysms (widening and weakening of the artery wall) and later can lead to narrowing or stenosis reducing the blood supply to the heart.
On 5 October 2026, CSL and the Swiss company Alentis Therapeutics announced a global partnership to develop lixudebart. This study medicine is aimed at AAV with rapidly progressive glomerulonephritis (AAV-RPGN), the form in which kidney function can decline within days or weeks.
Since avacopan was taken off the European market, many patients with GPA or MPA ask: is anyone else working on medicines that could reduce our use of corticosteroids such as prednisolone? The answer is yes, but it will likely take several years before they reach patients.
On 7 November 2026, the Italian patient association APACS will bring people living with EGPA, their families and clinicians together in Milan for a day of learning and open discussion.
